Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | SWOG S1416: cisplatin +/- veliparib in TNBC

Priyanka Sharma • 29 May 2020
ASCO 2020
Breast Cancer Cisplatin Veliparib
SWOG S1416

Priyanka Sharma, MD, University of Kansas Medical Center, Westwood, KS, USA, discusses results from the phase II randomized trial (NCT02595905) of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals